Wedbush Initiates Blueprint Medicines At Outperform, Calls It A 'Template For Targeted Therapies'

By: via Benzinga
Wedbush initiated coverage on Blueprint Medicines Corp (NASDAQ: BPMC) Friday with an Outperform rating and $41 price ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.